Guidance for the 2023/24 financial year
September 13 2023 - 1:45PM
Guidance for the 2023/24 financial year
ANNOUNCEMENT NO.
242
13 September 2023
Guidance for the 2023/24 financial
year
ChemoMetec has today approved the annual report
for 2022/23, including the guidance for 2023/24, which is
considered inside information.
For 2023/24, ChemoMetec expects revenue in the
range of DKK 400-435 million (2022/23: DKK 442.3 million) and
EBITDA in the range of DKK 200-220 (2022/23: DKK 251.0
million).
The annual report for 2022/23, which is released
along with this announcement, sets out the underlying assumptions
applied in the preparation of the guidance for 2023/24.
Additional information
Rasmus Kofoed, CEO Tel.: (+45) 26 72 68
19
Niels Høy Nielsen, CFO Tel.: (+45) 25 51 87
24
About
ChemoMetec A/S
ChemoMetec develops, manufactures and markets
instruments for cell counting and a wide range of other
measurements. ChemoMetec’s instruments are marketed to the
pharmaceutical, biotech and agricultural industries worldwide.
ChemoMetec’s customers include some of the world’s leading
pharmaceutical companies, such as Novartis, Novo Nordisk, H.
Lundbeck, Merck, AstraZeneca and Johnson & Johnson.
ChemoMetec was founded in 1997 and is listed on
Nasdaq OMX Copenhagen. For further information, go to
www.chemometec.com.
Chemometec AS (TG:CHY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Chemometec AS (TG:CHY)
Historical Stock Chart
From Jul 2023 to Jul 2024